

Consensus or Controversy? Documenting and Discussing Investigators' Approaches to the Management of Ovarian Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III MONO-OLA1 study is evaluating olaparib monotherapy as first-line maintenance therapy in which patient population?
 - a. Patients who have undergone suboptimal debulking surgery
 - b. Patients with BRCA wild type, homologous recombination deficiency (HRD)-positive ovarian cancer
 - c. Patients with BRCA wild type, HRD-negative ovarian cancer
2. In the Phase II PICCOLO trial, promising response rates were reported with mirvetuximab soravtansine in which of the following settings?
 - a. Platinum-resistant recurrent ovarian cancer with ultralow FR α expression
 - b. Platinum-resistant recurrent ovarian cancer with FR α expression >25%
 - c. Platinum-sensitive recurrent ovarian cancer
 - d. As first-line maintenance therapy for patients with BRCA wild-type, HRD-negative ovarian cancer
3. Data from the Phase III ROSELLA trial comparing relacorilant with nab paclitaxel to nab paclitaxel alone for patients with platinum-resistant ovarian cancer report which of the following outcomes with the combination?
 - a. A progression-free survival (PFS) benefit but not an overall survival (OS) benefit
 - b. A PFS benefit and an OS benefit
 - c. Neither a PFS benefit nor an OS benefit
4. Results from the Phase III KEYNOTE-B96 trial evaluating the addition of pembrolizumab to weekly paclitaxel with or without bevacizumab for patients with platinum-resistant advanced ovarian cancer reported which efficacy finding?
 - a. No significant difference in OS
 - b. A statistically significant improvement in OS for only those patients whose tumors express PD-L1
 - c. A statistically significant improvement in OS for all comers
5. What was the approximate objective response rate with raludotatug deruxtecan for patients with platinum-resistant advanced ovarian cancer across all doses evaluated in the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study?
 - a. 15%
 - b. 25%
 - c. 50%
 - d. 85%